+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Breast Cancer Drugs Market Research Report by Type (Anti-metabolites, Aromatase inhibitor, and CDK 4/6 inhibitor), Distribution Channel, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 229 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4896792
UP TO OFF until Dec 31st 2022
The Global Breast Cancer Drugs Market size was estimated at USD 18.09 billion in 2021, USD 19.84 billion in 2022, and is projected to grow at a CAGR 9.86% to reach USD 31.81 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Breast Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Anti-metabolites, Aromatase inhibitor, CDK 4/6 inhibitor, HER2 inhibitor, Hormonal receptor, and Mitotic inhibitor.
  • Based on Distribution Channel, the market was studied across Ambulatory Surgical Centres, Clinics, Hospitals, Online Channels, and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Breast Cancer Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Drugs Market, including A. Menarini Industrie Farmaceutiche Riunite Srl, Abbott Laboratories Inc., AbbVie, Inc., Amgen Inc., Astellas Pharma, Inc., AstraZeneca Plc, Aurora Biopharma, Inc., BioNumerik Pharmaceuticals Inc., BRISTOL-MYERS SQUIBB, Celgene Corporation, Celldex Therapeutics, Eli Lilly and Company, F. Hoffman-La Roche Pvt. Ltd, FRESENIUS KABI AG, Genentech, Inc., Genzyme Corporation, Gilead Science, Inc., GlaxoSmithKline PLC, GRIFOLS S.A., Johnson & Johnson, Jounce Therapeutics, Inc., MacroGenics Inc., Merck & Co. Inc., Mylan N.V., Novartis AG, Onyx Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sorrento Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd., Tessa Therapeutics Pte Ltd., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and ZIOPHARM Oncology, Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Breast Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Breast Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Breast Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Drugs Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of breast cancer and rising geriatric population of women
5.1.1.2. Urbanization and adoption of unhealthy lifestyle
5.1.1.3. Improved advancements and research in drug technologies
5.1.2. Restraints
5.1.2.1. Adverse side effects caused by the use of breast cancer drugs
5.1.3. Opportunities
5.1.3.1. Increasingly collaboration and partnership among drug manufacturing companies
5.1.3.2. Growth in government initiatives and programs to spread awareness about breast cancer
5.1.4. Challenges
5.1.4.1. Stringent regulation on drug manufacturing process
5.2. Cumulative Impact of COVID-19
6. Breast Cancer Drugs Market, by Type
6.1. Introduction
6.2. Anti-metabolites
6.3. Aromatase inhibitor
6.4. CDK 4/6 inhibitor
6.5. HER2 inhibitor
6.6. Hormonal receptor
6.7. Mitotic inhibitor
7. Breast Cancer Drugs Market, by Distribution Channel
7.1. Introduction
7.2. Ambulatory Surgical Centres
7.3. Clinics
7.4. Hospitals
7.5. Online Channels
7.6. Retail Pharmacies
8. Americas Breast Cancer Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Breast Cancer Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Breast Cancer Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. A. Menarini Industrie Farmaceutiche Riunite Srl
12.2. Abbott Laboratories Inc.
12.3. AbbVie, Inc.
12.4. Amgen Inc.
12.5. Astellas Pharma, Inc.
12.6. AstraZeneca Plc
12.7. Aurora Biopharma, Inc.
12.8. BioNumerik Pharmaceuticals Inc.
12.9. BRISTOL-MYERS SQUIBB
12.10. Celgene Corporation
12.11. Celldex Therapeutics
12.12. Eli Lilly and Company
12.13. F. Hoffman-La Roche Pvt. Ltd
12.14. FRESENIUS KABI AG
12.15. Genentech, Inc.
12.16. Genzyme Corporation
12.17. Gilead Science, Inc.
12.18. GlaxoSmithKline PLC
12.19. GRIFOLS S.A.
12.20. Johnson & Johnson
12.21. Jounce Therapeutics, Inc.
12.22. MacroGenics Inc.
12.23. Merck & Co. Inc.
12.24. Mylan N.V.
12.25. Novartis AG
12.26. Onyx Pharmaceuticals, Inc.
12.27. Pfizer Inc.
12.28. Sanofi S.A.
12.29. Sorrento Therapeutics, Inc.
12.30. Sun Pharmaceutical Industries Ltd.
12.31. Takeda Pharmaceutical Company Ltd.
12.32. Tessa Therapeutics Pte Ltd.
12.33. Teva Pharmaceutical Industries Ltd.
12.34. Valeant Pharmaceuticals International, Inc.
12.35. ZIOPHARM Oncology, Inc.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL BREAST CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL BREAST CANCER DRUGS MARKET DYNAMICS
FIGURE 8. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 9. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2027
FIGURE 11. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 18. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 19. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, 2019-2027 (USD BILLION)
FIGURE 20. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 21. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, 2019-2027 (USD BILLION)
FIGURE 22. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 23. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 24. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD BILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 26. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, 2019-2027 (USD BILLION)
FIGURE 27. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 28. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, 2019-2027 (USD BILLION)
FIGURE 29. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 30. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD BILLION)
FIGURE 31. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 32. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, 2019-2027 (USD BILLION)
FIGURE 33. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD BILLION)
FIGURE 35. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 36. AMERICAS BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 38. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 40. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. BRAZIL BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. CANADA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. MEXICO BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 46. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 47. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2027
FIGURE 48. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 50. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 52. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. CHINA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. INDIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. INDONESIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. JAPAN BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. TAIWAN BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. THAILAND BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 66. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 67. FRANCE BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 68. GERMANY BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. ITALY BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 71. QATAR BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 72. RUSSIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 73. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 74. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 75. SPAIN BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 76. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 77. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 78. GLOBAL BREAST CANCER DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 79. GLOBAL BREAST CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 80. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BREAST CANCER DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL BREAST CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 6. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY REGION, 2019-2027 (USD BILLION)
TABLE 7. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY ANTI-METABOLITES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 12. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 17. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 19. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY CDK 4/6 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 22. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 24. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY HER2 INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 27. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 28. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 29. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY HORMONAL RECEPTOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY REGION, 2019-2027 (USD BILLION)
TABLE 32. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 33. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY STATE, 2019-2027 (USD BILLION)
TABLE 34. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY MITOTIC INHIBITOR, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 37. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2019-2027 (USD BILLION)
TABLE 38. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY STATE, 2019-2027 (USD BILLION)
TABLE 40. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 43. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 44. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 45. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2019-2027 (USD BILLION)
TABLE 48. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD BILLION)
TABLE 50. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2019-2027 (USD BILLION)
TABLE 53. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 54. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY STATE, 2019-2027 (USD BILLION)
TABLE 55. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. GLOBAL BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD BILLION)
TABLE 58. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 59. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD BILLION)
TABLE 60. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 62. AMERICAS BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 64. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 65. AMERICAS BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 66. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 68. ARGENTINA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 69. BRAZIL BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. BRAZIL BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 71. BRAZIL BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 72. CANADA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. CANADA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 74. CANADA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 75. MEXICO BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. MEXICO BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 77. MEXICO BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 78. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 80. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 81. UNITED STATES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 82. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 84. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 85. ASIA-PACIFIC BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 86. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 88. AUSTRALIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 89. CHINA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. CHINA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 91. CHINA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 92. INDIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 93. INDIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 94. INDIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 95. INDONESIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 96. INDONESIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 97. INDONESIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 98. JAPAN BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 99. JAPAN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 100. JAPAN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 101. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 102. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 103. MALAYSIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 104. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 105. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 106. PHILIPPINES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 107. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 108. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 109. SINGAPORE BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 110. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 111. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 112. SOUTH KOREA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 113. TAIWAN BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 114. TAIWAN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 115. TAIWAN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 116. THAILAND BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 117. THAILAND BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 118. THAILAND BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 123. FRANCE BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 124. FRANCE BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 125. FRANCE BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 126. GERMANY BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 127. GERMANY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 128. GERMANY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 129. ITALY BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 130. ITALY BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 131. ITALY BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 132. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 133. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 134. NETHERLANDS BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 135. QATAR BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 136. QATAR BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 137. QATAR BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 138. RUSSIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 139. RUSSIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 140. RUSSIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 141. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 142. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 143. SAUDI ARABIA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 144. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 145. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 146. SOUTH AFRICA BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 147. SPAIN BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 148. SPAIN BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 149. SPAIN BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 150. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 151. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 152. UNITED ARAB EMIRATES BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 153. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 154. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 155. UNITED KINGDOM BREAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD BILLION)
TABLE 156. GLOBAL BREAST CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 157. GLOBAL BREAST CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 158. GLOBAL BREAST CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 159. GLOBAL BREAST CANCER DRUGS MARKET RANKING
TABLE 160. GLOBAL BREAST CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 161. GLOBAL BREAST CANCER DRUGS MARKET MERGER & ACQUISITION
TABLE 162. GLOBAL BREAST CANCER DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 163. GLOBAL BREAST CANCER DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 164. GLOBAL BREAST CANCER DRUGS MARKET INVESTMENT & FUNDING
TABLE 165. GLOBAL BREAST CANCER DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 166. GLOBAL BREAST CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abbott Laboratories Inc.
  • AbbVie, Inc.
  • Amgen Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Aurora Biopharma, Inc.
  • BioNumerik Pharmaceuticals Inc.
  • BRISTOL-MYERS SQUIBB
  • Celgene Corporation
  • Celldex Therapeutics
  • Eli Lilly and Company
  • F. Hoffman-La Roche Pvt. Ltd
  • FRESENIUS KABI AG
  • Genentech, Inc.
  • Genzyme Corporation
  • Gilead Science, Inc.
  • GlaxoSmithKline PLC
  • GRIFOLS S.A.
  • Johnson & Johnson
  • Jounce Therapeutics, Inc.
  • MacroGenics Inc.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sorrento Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Tessa Therapeutics Pte Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • ZIOPHARM Oncology, Inc.

Methodology

Loading
LOADING...